We use cookies to help provide you with the best possible online experience. By using this site, you agree that we may store and access cookies on your device. You can find out more about how to set your own preferences here.
Accept cookies

Cerbios confirmed by D&B in the top 500 Swiss companies with Risk Indicator 1

Lugano / Barbengo, August 08 2011

In June 2011, Cerbios received from Dun & Bradstreet the newly issued Rating Certificate confirming Cerbios as a company with Risk Indicator of 1 (D&B Risk Indicators range from 1, minimum risk, to 4, high risk). As a result, Cerbios now appears in the updated Swiss top 500 companies published by D&B (www.top-rating.ch). Top rating companies are characterized by financial stability and a top or high credit standing (irrespective of the size of their company).

“It is a satisfaction to receive this external certification which confirms the robust financial situation and success of the company strategy decided by the board several years ago. In these difficult times, the financial stability of a supplier is of great importance, because it provides the confidence that the supply of APIs from the qualified source will continue in the coming years without putting in trouble the registration’s owner” says Dr. Gabriel Haering, Cerbios’ CEO.

In fact, the bankruptcy of an API supplier (single source) could have a dramatic impact on loosing the market for 3-4 years, with no guarantee of full recovery once a new source has been approved. This takes into consideration the fact that the timeline for approving a new source of API from the actual authorities is getting longer and longer (estimates of > 2 years) and this on top of all the required regulatory activities (1-2 years work).

Medium-large pharma companies are already applying a risk assessment approach when choosing an API supplier (asking for all relevant financial indicators). Biotech and small pharma companies have not evolved this far and are working more on “price” than on “value”, where financial stability would enter into account. Considering the fact that the majority of biotech companies have as an exit strategy the “licensing-out” of their NCE of NBE, choosing the cheaper supplier could in fact lower the value of the licensing deal (identifying risk in the assessment of the CMC) or even put the licensing deal in danger (poorly performed work could require a complete re-engineering of the CMC, creating a delay in the launch of a project therefore costing millions of dollarsè loss of interest).

About Cerbios-Pharma SA

Cerbios is a privately held company located in Lugano, Switzerland, that specializes in the development and manufacture of both chemical and biological APIs for its partners world-wide.

Exclusive, third-party manufacturing services are offered by the Chemical Division for HPAIs and by the Biological Division for monoclonal antibodies, recombinant proteins and pharma probiotics.

Cerbios provides full CMC support to its world-wide partners, including the supply of cGMP clinical batches, registration/validation material and commercially manufactured APIs. Paramount to this is the ability to supply all of the technical documentation and support necessary for a successful registration. Cerbios’ commercial products are marketed worldwide but primarily in Europe, USA, Japan and India.
[[ getItemTitle(currentIndex) ]]